Trial Profile

A phase 2a study of HT-6184 in low-risk myelodysplastic syndrome patients

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HT-6184 (Primary) ; Darbepoetin alfa; Epoetin alfa
Indications Myelodysplastic syndromes
Focus Proof of concept; Therapeutic Use

Most Recent Events

04 Jun 2025 According to a Halia Therapeutics media release, an interim analysis was conducted following Stage 1, and topline results from the complete study are expected later this year.
04 Jun 2025 According to a Halia Therapeutics media release, this two-stage study enrolled 18 evaluable patients in Stage 1 and has now completed enrollment of an additional 15 participants in Stage 2.
04 Jun 2025 According to a Halia Therapeutics media release, status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com